SHANGHAI – China-based Ascentage Pharma Group said APG-1387 is set to enter phase I trials as a new chemical entity under the Chinese 1.1 drug classification, a special category for innovative therapies not approved in other countries. An oncology-focused biotech, Ascentage said it is the first in China to push forward an apoptosis candidate using a made-in-China molecule.